Congqin Chen
Overview
Explore the profile of Congqin Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen C, Chen C, Cao L, Fang J, Xiao J
Int Immunopharmacol
. 2024 Apr;
133:112022.
PMID: 38615382
Objectives: Bivalent COVID-19 mRNA vaccines, which contain two different components, were authorized to provide protection against both the original strain of SARS-CoV-2 and the Omicron variant as a measure to...
2.
Ding L, Chen C, Yang Y, Zhang X
Front Immunol
. 2024 Feb;
15:1349636.
PMID: 38384460
Objective: Over the years when biologic psoriasis therapies (TNF inhibitors, IL-12/23 inhibitors, IL-23 inhibitors, and IL-17 inhibitors) have been used in psoriasis patients, reports of major cardiovascular events (MACEs) have...
3.
Chen C, Zhou R, Fu F, Xiao J
Eur Psychiatry
. 2023 Nov;
66(1):e99.
PMID: 38031404
Background: Recent reports of individuals experiencing suicidal and/or self-injurious behaviors while using liraglutide and semaglutide have heightened the concerns regarding neuropsychiatric safety of Glucagon-like peptide-1 agonists (GLP-1RAs). As real-world evidence...
4.
Chen C, Xie D, Xiao J
Front Pharmacol
. 2023 May;
14:1100617.
PMID: 37124218
Autoimmune hepatitis (AIH) has occasionally been reported after administration of Coronavirus Disease 2019 (COVID-19) vaccine. The present study aimed to investigate the reported rate and disproportionality of AIH following COVID-19...
5.
Chen C, Ding L, Fu F, Xiao J
CNS Neurosci Ther
. 2023 Mar;
29(9):2548-2554.
PMID: 36971193
Aim: Sacubitril/valsartan is a new cardiovascular agent characterized by its dual inhibition on the reninangiotensin system (RAS) and the neprilysin. As neprilysin also involved itself in the degradation of amyloid-β,...
6.
Chen C, Fu F, Ding L, Fang J, Xiao J
Front Immunol
. 2022 Sep;
13:938322.
PMID: 36172346
Background: Despite the likely association between coronavirus 2019 (COVID-19) mRNA vaccines and cases of myocarditis/pericarditis, the benefit-risk assessment by the Centers for Disease Control (CDC) still showed a favorable balance...
7.
Chen C, Fu F, Ding L, Xiao J
J Clin Pharm Ther
. 2022 Sep;
47(11):1789-1795.
PMID: 36089844
What Is Known And Objective: Evidence on whether the coronavirus disease 2019 (COVID-19) vaccination could cause hearing-related adverse events is still conflicting. This study aims to access the association between...
8.
Ding L, Chen C, Yang Y, Fang J, Cao L, Liu Y
Cardiovasc Ther
. 2022 Feb;
2022:9866486.
PMID: 35140810
Background: Some studies suggest that potential safety issues about PCSK9 inhibitors have not been sufficiently explored in clinical trials, including musculoskeletal adverse events (MAEs). Objective: To examine the association between...
9.
Fang J, Chen C, Wu Y, Zhang M, Zhang Y, Shi G, et al.
Ann Transl Med
. 2020 May;
8(7):493.
PMID: 32395537
Background: The objectives of the present prospective observational study conducted in patients receiving conventional dosage of linezolid was to define the pharmacodynamic range of linezolid exposure, to assess the inter-individual...
10.
Chen C, Zhang M, Chen H, Fang J
Ther Drug Monit
. 2020 Mar;
42(4):515-517.
PMID: 32217880
We presented a case of subtherapeutic linezolid concentration in a patient with bullous pemphigoid characterized by large area skin anabrosis complicated by methicillin-resistant Staphylococcus aureus infections.